<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597086</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-20091</org_study_id>
    <secondary_id>NCI-2020-07234</secondary_id>
    <nct_id>NCT04597086</nct_id>
  </id_info>
  <brief_title>Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients</brief_title>
  <official_title>The Effects of Bright White Light Therapy on Fatigue, Sleep, Distress, Depression and Anxiety in the Hospitalized Leukemia Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates how well bright white light therapy works in improving sleep,&#xD;
      fatigue, distress, depression, and anxiety, side effects that are often experienced during an&#xD;
      intense leukemia treatment regimen, in hospitalized leukemia patients. Bright white light&#xD;
      therapy may help to control these symptoms, and information from this study may help doctors&#xD;
      and nurses learn more about methods for decreasing these symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the efficacy of bright white light therapy (BWLT) on fatigue in patients&#xD;
      diagnosed with leukemia during their hospitalization.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the efficacy of BWLT on sleep disturbance in patients diagnosed with leukemia&#xD;
      during their hospitalization.&#xD;
&#xD;
      I. To assess the efficacy of BWLT on anxiety in patients diagnosed with leukemia during their&#xD;
      hospitalization.&#xD;
&#xD;
      III. To assess the efficacy of BWLT on depression in patients diagnosed with leukemia during&#xD;
      their hospitalization.&#xD;
&#xD;
      IV. To assess the efficacy of BWLT on distress in patients diagnosed with leukemia during&#xD;
      their hospitalization.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP I: Patients receive BWLT over 30 minutes in addition to standard of care daily during&#xD;
      hospital stay.&#xD;
&#xD;
      GROUP II: Patients receive standard of care during hospital stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of fatigue</measure>
    <time_frame>Up to one month after discharge</time_frame>
    <description>Will be assessed by Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue. Will fit a mixed model of fatigue as a function of time and group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep disturbance</measure>
    <time_frame>Up to one month after discharge</time_frame>
    <description>Will be assessed by PROMIS-Sleep Disturbance. Will fit a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Up to one month after discharge</time_frame>
    <description>Will be assessed by General Anxiety Disorder-7. Will fit a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Up to one month after discharge</time_frame>
    <description>Will be assessed by Patient Health Questionnaire Depression Scale. Will fit a mixed model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distress</measure>
    <time_frame>Up to one month after discharge</time_frame>
    <description>Will be assessed by Distress Thermometer. Will fit a mixed model.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Recurrent Leukemia</condition>
  <condition>Refractory Leukemia</condition>
  <arm_group>
    <arm_group_label>Group I (BWLT, best practice)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BWLT over 30 minutes in addition to standard of care daily during hospital stay.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care during hospital stay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive standard of care</description>
    <arm_group_label>Group I (BWLT, best practice)</arm_group_label>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bright White Light Therapy</intervention_name>
    <description>Receive BWLT</description>
    <arm_group_label>Group I (BWLT, best practice)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (BWLT, best practice)</arm_group_label>
    <arm_group_label>Group II (standard of care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted to the Acute Leukemia Unit for an anticipated stay of 3 weeks or longer&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Able to comprehend and sign a consent form&#xD;
&#xD;
          -  Able to read and complete surveys&#xD;
&#xD;
          -  Alert and oriented&#xD;
&#xD;
          -  Without BWLT for seven days prior to initiating the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current eye disorders which is defined as:&#xD;
&#xD;
               -  Iritis, uveitis, keratitis, cataract, glaucoma, macular degeneration, retinal&#xD;
                  detachment, or retinitis pigmentosa&#xD;
&#xD;
          -  Diagnosed bipolar disorder&#xD;
&#xD;
          -  Persons with pacemakers&#xD;
&#xD;
               -  The manufacturer of the BWLT unit used for this study mentions the light unit&#xD;
                  contains magnets&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shelly Brown, MS, APRN-CNS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Brown, MS, APRN-CNS</last_name>
      <phone>614-293-2598</phone>
      <email>shelly.brown@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Shelly Brown, MS, APRN-CNS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Shelly Brown</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

